2006 proposed fee schedule - American Society of Clinical Oncology
2006 proposed fee schedule - American Society of Clinical Oncology 2006 proposed fee schedule - American Society of Clinical Oncology
340 Non-Facility Facility % % HCPCS MOD DESCRIPTION Follow-up Old New Change Old New Change 99262 inpatient consult Follow-up N/A N/A N/A $45.48 $43.50 -4% 99263 inpatient consult Emergency dept N/A N/A N/A $67.46 $64.57 -4% 99283 visit Emergency dept N/A N/A N/A $62.15 $59.30 -5% 99284 visit Critical care, first N/A N/A N/A $97.02 $92.54 -5% 99291 hour Critical care, $256.57 $243.87 -5% $207.68 $198.33 -4% 99292 addÏl 30 min Nursing facility $113.69 $108.60 -4% $103.84 $99.17 -4% 99302 care Nursing facility $87.92 $84.00 -4% $87.92 $84.00 -4% 99303 care Nursing fac care, $108.39 $103.43 -5% $108.39 $103.43 -5% 99312 subseq Nursing fac care, $56.47 $54.03 -4% $56.47 $54.03 -4% 99313 subseq Home visit, est $79.58 $76.18 -4% $79.58 $76.18 -4% 99348 patient Home visit, est $72.01 $68.65 -5% N/A N/A N/A 99350 patient Immunization $164.48 $156.46 -5% N/A N/A N/A G0008 admin ESRD related $18.57 $17.88 -4% N/A N/A N/A G0317 svs 4+mo 20+yrs Initial preventive $307.73 $294.91 -4% $307.73 $294.91 -4% G0344 exam EKG for initial $97.40 $93.69 -4% $72.76 $69.47 -5% G0366 prevent exam EKG tracing for $26.91 $24.23 -10% N/A N/A N/A G0367 initial prev EKG interpret & $17.81 $15.42 -13% N/A N/A N/A G0368 report preve $9.10 $8.81 -3% $9.10 $8.81 -3% In the November 15, 2004 PFS final rule, we showed the combined impact of PFS and drug payment changes on the total revenues for specialties that perform a significant volume of drug administration services. (69 FR 66406) Although we have not performed a similar combined impact analysis this year for all of the specialties considered last year, we
341 have undertaken a similar analysis of hematology/oncology. In last year’s final rule, we announced a one-year demonstration to collect information about symptoms for cancer patients receiving chemotherapy (69 FR 66308). Although this demonstration was implemented through the Secretary’s authority under sections 402(a)(1)(B) and 402(a)(2) of the Social Security Act Amendments of 1967 (Pub. L. 90-248) and not through administrative rulemaking, we discussed the impacts of the additional payments from this demonstration in last year’s final rule impact analysis. Therefore, we are also including an analysis of the impact on payments to hematology/oncology as this demonstration project ends. As indicated in Table 35 below, PFS services account for approximately 28 percent of Medicare revenues for hematology/oncology. Medicare payments for all PFS services provided by the specialties of hematology/oncology are projected to decrease by 5.2 percent for 2006. We estimate the impact of the one-year demonstration was 15 percent higher payments relative to PFS payments during 2005. We estimate that approximately 69 percent of total Medicare revenues for hematology/oncology are attributed to drugs, and, for purposes of this analysis, we are assuming no change in the payment levels for Part B drugs during 2006. Assuming no changes in utilization for
- Page 289 and 290: 289 can issue a final determination
- Page 291 and 292: 291 conclude that Hispanic persons
- Page 293 and 294: 293 nuclear medicine services in ei
- Page 295 and 296: adiopharmaceuticals. In the final r
- Page 297 and 298: 297 (including Nuclear Medicine and
- Page 299 and 300: we would resolve any doubt on the m
- Page 301 and 302: facility payment rather than a TC c
- Page 303 and 304: ventures and leases, pose a risk of
- Page 305 and 306: 305 Underlying the projected rate r
- Page 307 and 308: decisions are central to the health
- Page 309 and 310: however. We are particularly intere
- Page 311 and 312: The collection requirement in this
- Page 313 and 314: eporting requirements are discussed
- Page 315 and 316: IV. Response to Comments Because of
- Page 317 and 318: achieve the objectives with less si
- Page 319 and 320: 319 The analysis and discussion pro
- Page 321 and 322: 321 for a new code may change becau
- Page 323 and 324: 323 TABLE 30--Impact of Practice Ex
- Page 325 and 326: hour for these specialties. As note
- Page 327 and 328: Both physical/occupational therapy
- Page 329 and 330: 329 proposing to add cardiology cat
- Page 331 and 332: Speciality Impact of Removing Aberr
- Page 333 and 334: Family TABLE 32--Impact of Multiple
- Page 335 and 336: 335 column includes the current est
- Page 337 and 338: Specialty Medicare Allowed Charges
- Page 339: 339 Non-Facility Facility % % HCPCS
- Page 343 and 344: of the updated GPCI data. For the R
- Page 345 and 346: C. Medicare Telehealth Services In
- Page 347 and 348: 347 TABLE 37--Impact of Proposed Ch
- Page 349 and 350: 349 of the increase to the drug add
- Page 351 and 352: plus current AAP priced drug paymen
- Page 353 and 354: 353 the center up to what it would
- Page 355 and 356: satisfies the requirements of the i
- Page 357 and 358: 357 certainty the extent of these s
- Page 359 and 360: delivery arrangements and would hel
- Page 361 and 362: List of Subjects 42 CFR Part 405 Ad
- Page 363 and 364: (including by refunding amounts in
- Page 365 and 366: (2) Any financial incentives provid
- Page 367 and 368: 7. The authority citation for part
- Page 369 and 370: * * * * * PART 413--PRINCIPLES OF R
- Page 371 and 372: 371 D. Redesignating paragraphs (l)
- Page 373 and 374: 373 (3) The additional nursing hour
- Page 375 and 376: cost components relating to trainin
- Page 377 and 378: CAPD and CCPD) when the facility ac
- Page 379 and 380: Indirect Sales means from the manuf
- Page 381 and 382: amount for the quarter to the neare
- Page 383 and 384: 383 25. The heading for Part 426 is
- Page 385 and 386: 385 (Catalog of Federal Domestic As
- Page 387 and 388: 1. CPT/HCPCS code. This is the CPT
- Page 389 and 390: grace period. This indicator is no
341<br />
have undertaken a similar analysis <strong>of</strong> hematology/oncology.<br />
In last year’s final rule, we announced a one-year<br />
demonstration to collect information about symptoms for<br />
cancer patients receiving chemotherapy (69 FR 66308).<br />
Although this demonstration was implemented through the<br />
Secretary’s authority under sections 402(a)(1)(B) and<br />
402(a)(2) <strong>of</strong> the Social Security Act Amendments <strong>of</strong> 1967<br />
(Pub. L. 90-248) and not through administrative rulemaking,<br />
we discussed the impacts <strong>of</strong> the additional payments from<br />
this demonstration in last year’s final rule impact<br />
analysis.<br />
Therefore, we are also including an analysis <strong>of</strong> the<br />
impact on payments to hematology/oncology as this<br />
demonstration project ends. As indicated in Table 35 below,<br />
PFS services account for approximately 28 percent <strong>of</strong><br />
Medicare revenues for hematology/oncology. Medicare<br />
payments for all PFS services provided by the specialties <strong>of</strong><br />
hematology/oncology are projected to decrease by 5.2 percent<br />
for <strong>2006</strong>. We estimate the impact <strong>of</strong> the one-year<br />
demonstration was 15 percent higher payments relative to PFS<br />
payments during 2005. We estimate that approximately 69<br />
percent <strong>of</strong> total Medicare revenues for hematology/oncology<br />
are attributed to drugs, and, for purposes <strong>of</strong> this analysis,<br />
we are assuming no change in the payment levels for Part B<br />
drugs during <strong>2006</strong>. Assuming no changes in utilization for